AN AUTHORITATIVE RESOURCE FOR EVERYTHING ABOUT CANCER
Perspectives
This section features opinion pieces, reflections, and expert commentary on timely or overlooked issues in cancer care, research, and the oncology workforce.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Melanoma Monday 2025: On Skin Cancer Prevention & Awareness
By The Cancer News Team
This article spotlights Melanoma Monday 2025 with expert insights from Dr. Shailender Bhatia on melanoma prevention, early detection, and treatment advancements.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Implementation Science In Cancer: Where Are We Today?
By The Cancer News Team
This article explores implementation science in cancer care, with insights from Fred Hutch’s Dr. Mazyar Shadman and the efforts of Binaytara and Dr. Binay Shah to reduce cancer disparities in LMICs.
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Zuma 7 trial shows statistically significant overall survival benefit for yescarta
By Editorial Team
By Dr. Luke Fletcher [Willamette Valley Cancer Institute & Research Center](https://www.oregoncancer.com/) _The Zuma 7 trial is a randomized, open-label multicenter study for patients with primary ref...
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
Volunteer Spotlight: June Zhu
By The Cancer News Team
Zhu Shares About Her Experience Volunteering at Binaytara
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching
By Editorial Team
The transformation of lung adenocarcinoma treatment through molecular targeting is one of oncology’s great recent successes.
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching
By Editorial Team
The transformation of lung adenocarcinoma treatment through molecular targeting is one of oncology’s great recent successes.
New Targets in Squamous NSCLC: Old Mechanisms, Novel Approaches, and Two Phase 3 Trials Worth Watching
By Editorial Team
The transformation of lung adenocarcinoma treatment through molecular targeting is one of oncology’s great recent successes.